Oppenheimer Asset Management Inc. Sells 7,173 Shares of STERIS plc (NYSE:STE)

Oppenheimer Asset Management Inc. cut its holdings in STERIS plc (NYSE:STE - Free Report) by 57.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,382 shares of the medical equipment provider's stock after selling 7,173 shares during the period. Oppenheimer Asset Management Inc.'s holdings in STERIS were worth $1,305,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Ashton Thomas Securities LLC acquired a new stake in STERIS during the third quarter worth about $25,000. Central Pacific Bank Trust Division acquired a new stake in shares of STERIS in the 3rd quarter valued at approximately $28,000. Quent Capital LLC boosted its stake in shares of STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Versant Capital Management Inc boosted its stake in shares of STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 181 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Down 0.8 %

Shares of STE stock traded down $1.79 during trading hours on Monday, hitting $218.33. 248,154 shares of the company were exchanged, compared to its average volume of 491,590. The firm has a market cap of $21.55 billion, a P/E ratio of 50.20 and a beta of 0.85. STERIS plc has a fifty-two week low of $195.47 and a fifty-two week high of $248.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The company has a 50 day simple moving average of $230.37 and a two-hundred day simple moving average of $228.59.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $2.12 by $0.02. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.03 EPS. Equities analysts anticipate that STERIS plc will post 9.15 EPS for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS's payout ratio is currently 52.05%.

Analyst Ratings Changes

A number of research analysts recently issued reports on STE shares. Piper Sandler upgraded shares of STERIS from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. KeyCorp raised their price objective on shares of STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. StockNews.com lowered shares of STERIS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, October 29th. JMP Securities reiterated a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a report on Monday. Finally, Stephens reiterated an "overweight" rating and issued a $260.00 price objective on shares of STERIS in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

Insider Activity at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at $10,603,710. The trade was a 35.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.14% of the stock is currently owned by insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.